In Science this week: reason for partial HIV vaccine protection, and more.
Investigators at the Walter Reed Army Institute and elsewhere identified human leukocyte antigen variants with ties to enhanced or diminished HIV vaccine protection.
The company aims to launch the qPCR-based test in sub-Saharan Africa.
The tests eligible for the collaboration include a quantitative HIV-1 viral load assay, as well as a qualitative test for active infection and early infant diagnosis.
The assays add to the test menu of Beckman Coulter's DxN Veris molecular diagnostics system.
The method combines array-based DNA synthesis, phage protein display, immunoprecipitation, and high-throughput sequencing.
An array of 15 HIV-1 recombinant protein and associated peptides matched very closely to ELISA results in evaluating the intricacies of associated antibody binding patterns.
The new cartridge-based test runs on the firm's GeneXpert platform and provides a 90-minute molecular diagnosis of HIV in high-risk individuals and infants.
The Phase II grant will provide the company with funding to develop a commercial-ready version of the test.
The HIV test is the first of several NGS-based infectious disease tests the company plans to develop, with a hepatitis C virus test following close behind.
CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.
Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.
Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.
In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.